It was very unusual to detect relatively rapidly fatal triple positive metachronous BC of the contralateral breast in the era of neoadjuvant dual antiestrogen and anti-HER-2-targeted therapies despite response to primary tumor. Here, ERBB2 is linked to breast cancer.